Considerable time and expense are often spent gathering and analyzing all the relevant data for confident, strategic decisions regarding your generics portfolio, best-fit active pharmaceutical ingredient (API) suppliers, and most feasible partners and markets to expand your business.
Optimize your generics portfolio by identifying the right products, right markets, right partners, and precise timing to meet your goals. Strategically develop your portfolio, find API suppliers, gain insight on when drugs go off patent, penetrate new markets, identify partners and monitor your competition with Newport, a Cortellis solution. If you’re an API manufacturer, take advantage of the same market, patent and API intelligence to find potential customers, anticipate the needs of finished dose companies, understand your competitors and stay competitive in your markets.
Develop better strategies that grow your business using trusted generics intelligence
Gain a competitive edge and stay on top of which generics and APIs are most likely to succeed. Quickly and thoroughly research new product and company opportunities using a single source of integrated data from Newport, including patents, sales, pack price, consumption, Paragraph IV patent challenges, API, market share, companies and launches.
"Newport has been a great investment for us, saving us time and money, while improving productivity."
Building and executing a strong portfolio strategy is crucial in your quest to be first-to-market or best-in-class. Understand the market landscape and pursue new opportunities while monitoring latest regulatory guidelines.
"Newport is embedded in my team’s workflow and is harnessed by Biophore every day."
To succeed in today’s highly competitive environment, you need to secure new product launches earlier, find cost-effective sources of supply, and stay compliant in an ever-changing regulatory environment. Accurately identify the earliest date a drug can go generic and assess market competitiveness. Determine API suppliers’ experience and capabilities using powerful analytics incorporating market, patent, and API data generated from primary research.
“One great thing about Newport is the distinction between confirmed and unconfirmed APIs – so we can see the complete picture straight away.”
Small molecules and biologics with synthesis schemes
Manufacturers and marketers
US, JP and SK DMF, COS and GMP certificates
Regions' sales data sourced
Countries' launch data available
Our accredited global alliance program delivers value-added solutions by combining offerings from Clarivate with other technology and service providers. Partner with us to drive profitable growth, increase revenue and deliver greater value to your customers.
Contact us to learn more about how you can gain a competitive edge in generics or API markets